Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: The experience of the PISCIS Cohort

Clinical Microbiology and Infection

Volumn 19, Issue 7, 2013, Pages 646-653

  Manzardo, C ^a   Esteve, A ^b,c,d   Ortega, N ^b,c,d   Podzamczer, D ^a   Murillas, J ^e   Segura, F ^f   Force, L ^g   Tural, C ^h   Vilaro J ⁱ   Masabeu, A ^j   Garcia, I ^k   Guadarrama, M ^l   Ferrer, E ^a   Riera, M ^e   Navarro, G ^f   Clotet, B ^h   Gatell, J M ^a   Casabona, J ^b   Miro J M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b GENERALITAT DE CATALUNYA   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^f HOSPITAL DE SABADELL   (Spain)

^g HOSPITAL DE MATARÓ   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ HOSPITAL GENERAL DE VIC   (Spain)

^j Hospital de Palamos   (Spain)

^k HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^l Hospital Alt Penedès Vilafranca   (Spain)

more..

Author keywords

Advanced patients; AIDS defining events; HIV 1; Pneumocystis jiroveci pneumonia; Prognostic factors; Survival; Timing of HAART; Tuberculosis

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

HUMAN IMMUNODEFICIENCY VIRUS 1; PNEUMOCYSTIS JIROVECII;

EID: 84878904722     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03991.x     Document Type: Article

References (23)

1. Palella FJ Jr, Deloria-Knoll M, Chmiel JS et al., HIV Outpatient Study Investigators. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003; 138: 620-626.
2. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-299.
3. Girardi E, Sabin CA, Monforte AD. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007; 46 (suppl 1): S3-S8.
4. Sabin CA, Smith CJ, Gumley H et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004; 18: 2145-2151.
5. Hocking JS, Rodger AJ, Rhodes DG, Crofts N. Late presentation of HIV infection associated with prolonged survival following AIDS diagnosis: characteristics of individuals. Int J STD AIDS 2000; 11: 503-508.
6. Schwarcz S, Hsu L, Dilley JW, Loeb L, Nelson K, Boyd S. Late diagnosis of HIV infection: trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS. J Acquir Immune Defic Syndr 2006; 43: 491-494.
7. Sobrino Vegas P, García San Miguel L, Caro-Murillo AM et al. Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. Curr HIV Res 2009; 7: 224-230.
8. Mussini C, Manzardo C, Johnson M et al. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS 2008; 22: 2461-2469.
9. French MA. Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy. Curr HIV/AIDS Rep 2007; 4: 16-21.
10. Manzardo C, Zaccarelli M, Agüero F, Antinori A, Miró JM. Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease. J Acquir Immune Defic Syndr 2007; 46 (suppl 1): S9-S18.
11. Zolopa A, Andersen J, Powderly W et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4: e5575.
12. Abdool Karim SS, Naidoo K, Grobler A et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706.
13. Abdool Karim SS, Naidoo K, Grobler A et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365: 1492-1501.
14. Blanc F-X, Sok T, Laureillard D et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365: 1471-1481.
15. Havlir DV, Kendall MA, Ive P et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365: 1482-1491.
16. Jaen A, Casabona J, Esteve A et al. Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project. Med Clin (Barc) 2005; 124: 525-531.
17. Jaen A, Esteve A, Miro JM et al. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy PISCIS Cohort (Spain). J Acquir Immune Defic Syndr 2008; 47: 212-220.
18. Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT). Sistema integrat de vigilància epidemiològica de la SIDA/VIH/ITS a Catalunya (SIVES). Barcelona: Generalitat de Catalunya, Departament de Salut, 2011. Document tècnic: núm. 20.
19. Borghi V, Girardi E, Bellelli S et al. Late presenters in an HIV surveillance system in Italy during the period 1992-2006. J Acquir Immune Defic Syndr 2008; 49: 282-286.
20. Velasco M, Castilla V, Sanz J et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. COMESEM Cohort. J Acquir Immune Defic Syndr 2009; 50: 148-152.
21. Török ME, Yen NTB, Chau TTH et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis 2011; 52: 1374-1383.
22. World Health Organization. Global tuberculosis control. Geneva: WHO, 2011. Available at: http://www.who.int/tb/publications/global_report/en/index.html (last accessed 18 November 2011).
23. Makadzange AT, Ndhlovu CE, Takarinda K et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa. Clin Infect Dis 2010; 50: 1532-1538.